Related Experiment Video
Updated: Aug 1, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study
Eric Descombes1, Filipe Martins2, Ould Maouloud Hemett3
1Service of Nephrology, Department of Internal Medicine, HFR Fribourg-Hôpital Cantonal, Fribourg, Switzerland. descombese@h-fr.ch.
Background:
In hemodialysis patients, post-dialysis treatment with intravenous antibiotics permits even severe infections to be managed on an outpatient basis. Cefepime is a fourth-generation cephalosporin with a broad spectrum of action in monotherapy. We report on the pharmacokinetics of cefepime in post-dialysis therapy.
Methods:
Since June 2012, twelve infections were treated with post-dialysis cefepime in 9 patients on high-flux hemodialysis. The initial post-dialysis dose of cefepime was approximately 15 mg/kg. The following doses were adapted according to the trough serum levels obtained before the subsequent dialysis in order to be above the EUCAST breakpoints for susceptible organisms and above the MIC90. Residual plasma concentrations were determined before (n = 30) and after (n = 17) dialysis by liquid chromatography-mass spectrometry.
Results:
Overall, the mean ± SD dose of cefepime was 920 ± 270 mg (14.5 ± 5.1 mg/kg), but it was significantly lower before the 48 h interval (775 ± 210 mg or 12.7 ± 4.5 mg/kg) compared to the 72 h interval (1125 ± 225 mg or 17.2 ± 4.9 mg/kg) (p < 0.05). The mean trough pre-dialysis concentrations were 10.7 ± 3.9 mg/l and 11.3 ± 5.6 mg/l at 48 and 72 h, respectively. These levels always largely exceeded the EUCAST susceptibility breakpoints for all the targeted bacteria (>1 mg/l) with the exception of Pseudomonas aeruginosa (>8 mg/l). Cefepime concentrations were higher in anuric patients compared to those with preserved diuresis (15.6 ± 3.5 vs 9.25 ± 3.6 mg/l; p < 0.001) and decreased on average by 81 % during dialysis (from 10.5 ± 3.7 to 1.96 ± 1.2 mg/l; p < 0.001). The clinical outcome of all patients was good.
Conclusions:
Outpatient treatment with cefepime administered post-dialysis three-times-weekly was effective and well-tolerated in our patients. According to our data, in patients infected by highly susceptible pathogens a fixed dose of cefepime of 1 g before every 48-h interval and of 1.5 g before every 72-h interval should be recommended, without need of routine monitoring of the cefepime blood levels. In patients having an infection with less susceptibles pathogens as P. aeruginosa, and particularly in those among them exhibiting residual renal function, higher initial doses are necessary (1.5 g before a 48-h interval and 2.0 g before a 72-h interval) with adaption according to the subsequent pre-dialysis trough serum levels.
Insights
Post-dialysis cefepime (a cephalosporin antibiotic) effectively treats infections in hemodialysis patients, allowing outpatient management. Dosing adjustments are recommended for specific pathogens like Pseudomonas aeruginosa and patients with residual renal function.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Intravenous antibiotic treatment post-hemodialysis enables outpatient management of severe infections.
- Cefepime, a fourth-generation cephalosporin, offers broad-spectrum antimicrobial activity for monotherapy.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical effectiveness of cefepime when administered post-dialysis in hemodialysis patients.
- To establish optimal dosing strategies for cefepime in this patient population.
Main Methods:
- A study involving 9 hemodialysis patients treated for 12 infections with post-dialysis cefepime.
- Dosing was initiated at approximately 15 mg/kg and adjusted based on trough serum levels measured before subsequent dialysis sessions.
- Liquid chromatography-mass spectrometry was used to determine cefepime concentrations in plasma before and after dialysis.
Main Results:
- Mean cefepime dose was 920 ± 270 mg, with significant differences between 48-h and 72-h intervals.
- Pre-dialysis cefepime levels consistently exceeded EUCAST susceptibility breakpoints, except for Pseudomonas aeruginosa.
- Cefepime concentrations were higher in anuric patients and decreased by approximately 81% during dialysis.
Conclusions:
- Outpatient, thrice-weekly post-dialysis cefepime administration is effective and well-tolerated for hemodialysis patients.
- Recommended fixed doses are 1g (48h) and 1.5g (72h) for susceptible pathogens, without routine monitoring.
- Higher doses and monitoring are advised for less susceptible pathogens (e.g., P. aeruginosa) and patients with residual renal function.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis III: Nursing Management
Continuous Renal Replacement Therapy
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management

